<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-PJKOT3TW/400409d1-ba37-41ad-b211-62d0cef17060/PDF"><dcterms:extent>84 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:DOC-PJKOT3TW/18270ea3-5060-4b15-8b4d-6f0f4a683c00/TEXT"><dcterms:extent>9 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="1994-2025"><edm:begin xml:lang="en">1994</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:DOC-PJKOT3TW"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-46R7GGHL" /><dcterms:issued>2008</dcterms:issued><dc:creator>Barbič-Žagar, Breda</dc:creator><dc:creator>Dular Meglič, Tina</dc:creator><dc:creator>Ristovski, Aleksandar</dc:creator><dc:format xml:lang="sl">številka:3</dc:format><dc:format xml:lang="sl">letnik:47</dc:format><dc:format xml:lang="sl">str. 309-312</dc:format><dc:identifier>ISSN:0025-8121</dc:identifier><dc:identifier>COBISSID:25427673</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-PJKOT3TW</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Medicinski razgledi</dc:publisher><dcterms:isPartOf xml:lang="sl">Medicinski razgledi</dcterms:isPartOf><dc:subject xml:lang="en">Bipolar Disorder</dc:subject><dc:subject xml:lang="sl">bipolarna motnja</dc:subject><dc:subject xml:lang="sl">Demenca</dc:subject><dc:subject xml:lang="en">Dementia</dc:subject><dc:subject xml:lang="en">Drug Therapy</dc:subject><dc:subject xml:lang="en">neurology</dc:subject><dc:subject xml:lang="sl">nevrologija</dc:subject><dc:subject xml:lang="sl">Osebnostne motnje</dc:subject><dc:subject xml:lang="en">Personality Disorders</dc:subject><dc:subject xml:lang="en">Pharmacology</dc:subject><dc:subject xml:lang="sl">Psihoze manično-depresivne</dc:subject><dc:subject xml:lang="en">Risperidon</dc:subject><dc:subject xml:lang="en">Risperidone</dc:subject><dc:subject xml:lang="en">Schizophrenia</dc:subject><dc:subject xml:lang="sl">Shizofrenija</dc:subject><dc:subject xml:lang="en">therapy</dc:subject><dc:subject xml:lang="en">Treatment Outcome</dc:subject><dc:subject xml:lang="sl">zdravljenje</dc:subject><dc:subject xml:lang="sl">Zdravljenje, izid</dc:subject><dc:subject rdf:resource="http://www.wikidata.org/entity/Q83042" /><dcterms:temporal rdf:resource="1994-2025" /><dc:title xml:lang="sl">Ocena učinkovitosti, varnosti in sprejemljivosti orodisperzibilnega risperidona pri bolnikih s shizofrenijo ali bipolarno manijo in pri vedenjskih motnjah dementnih bolnikov| Evaluation of efficacy, safety and acceptability of orodispersible risperidone in patients with schizophrenia, bipolar mania and behavioural disturbances in dementia patients|</dc:title><dc:description xml:lang="sl">Second generation antipsvchotics are currently the drugs of choice for the treatment of schizophrenia and bipolar mania, as well as for behavioural symptoms in patients with dementia. All these diseases represent an important healthcare problem in Europe, so that early treatment is recommended. Due to improved patient compliance, new pharmaceutical forms of already proven therapy are developed. Orally disintegrated tablets disintegrate rapidly in the mouth without water. Therefore, a study was conducted with risperidone (Torendo Q-Tab, Krka, d. d., Novo Mesto) in 487 patients with schizophrenia, bipolar mania and behavioural disturbances in dementia patients. Risperidone in recommended doses significantly improved symptoms in 77% of patients. Its tolerability was very good, as adverse reactions related to the medicine occurred in 11.9% of the patients. 90% of the patients were satisfied with treatment with Torendo Q-Tab, and this proved very good acceptability of our risperidone in the orodispersible formulation. The most frequent reason why patients choose Torendo Q-Tab wereČ easy swallowing of the medicine, easy administrationžintake of the medicine, ability to take it at anyplace and anytime, greater comfort that taking the medicine is less conspicuous, improved ability to perform everyday activities</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:DOC-PJKOT3TW"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:DOC-PJKOT3TW" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:DOC-PJKOT3TW/400409d1-ba37-41ad-b211-62d0cef17060/PDF" /><edm:rights rdf:resource="http://rightsstatements.org/vocab/InC/1.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Društvo Medicinski razgledi</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:DOC-PJKOT3TW/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:DOC-PJKOT3TW" /></ore:Aggregation></rdf:RDF>